In addition, reduced Cyp46a1 levels result in cognitive deficits, elevated production of β-amyloid peptides, and abnormal phosphorylation of tau (26) as well as in progressive loss of hippocampal neurons and an Alzheimer's disease–like phenotype (27). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.